On April 18, 2025, the highly anticipated “China Venture Annual Awards 2024” was officially released. Thanks to the firm’s strategic foresight in backing medical original innovations and its growing influence in early-stage life science investments, Baheal Pharma Group’s investment vehicle—BAHEAL ZHONGXIN CAPITAL—secured a place in the “2024 China Top 50 Corporate Direct‐Investment Funds”, underscoring its professional strength and industry influence in the early-stage life-health investment area.

On March 20, 2025, State Key Laboratory of Cardiovascular Disease officially opened in Shenzhen, accompanied by the inaugural meeting of its Academic Committee. The ceremony gathered senior government officials, leading scientists, and industry partners, including Huang Xiangyue, Party Secretary of Nanshan District; Wu Hongyan, Director of Shenzhen Municipal Health Commission; Chen Yihan, Academician of the Chinese Academy of Sciences and President of Shanghai East Hospital, Tongji University; Hu Shengshou, Academician of the Chinese Academy of Engineering, President of Fuwai Hospital, and Director of State Key Laboratory of Cardiovascular Disease; as well as Fu Gang, Chairman of Baheal Pharma Group.

On February 22, 2025, the "China Intracranial Metastases Consortium" (CLAIM) held its founding meeting and the first Xuanwu Intracranial Metastases Forum in Beijing. The event brought together nearly 170 experts and scholars from 108 hospitals, spanning oncology, radiotherapy, neurosurgery, pathology, and imaging departments, to discuss multidisciplinary approaches to treating intracranial metastases, intending to enhance patient survival.

February 13, 2025 - Qingdao Baheal Medical Co., Ltd. (hereinafter referred to as "Baheal Medical," 301015.SZ), a leading pharmaceutical industrialization platform, has announced a new commercial collaboration with Shanghai Roche Pharmaceuticals Ltd. ("Roche Pharmaceuticals China").

The Ministry of Science and Technology recently announced projects under the "14th Five-Year Plan" National Key R&D Program, prioritizing "Diagnostic Equipment and Biomedical Materials." Notably, for the first time, cardiac radiotherapy technology has been included as a focus area. The project "Development of Stereotactic Radiotherapy Technology and Prototype for Cardiac Arrhythmia," led by Huake Pioneer, a medical linear accelerator developer, was successfully selected.